Tender detail
Biosimilars: infliximab IV, tocilizumab IV and SC, denosumab SC, and epoetin alfa
Summary
IMELDA VZW is procuring biosimilar medicines under a four-lot framework agreement for supply to multiple locations from 2027 to 2028. The lots cover infliximab for intravenous use, tocilizumab for intravenous and subcutaneous use, denosumab for subcutaneous use, and epoetin alfa. The framework agreement has a total maximum value of €1,758,000.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.